Portal de Periódicos da CAPES

OVER EXPRESSION OF CLUSTERIN IS AN INDEPENDENT PROGNOSTIC FACTOR FOR NONPAPILLARY RENAL CELL CARCINOMA

2002; Lippincott Williams & Wilkins; Volume: 167; Issue: 2 Part 1 Linguagem: Inglês

10.1016/s0022-5347(01)69130-4

1527-3792

Hideaki Miyake, Shoji Hara, Soichi Arakawa, Sadao Kamidono, Isao Hara,

Clusterin in disease pathology

No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Feb 2002OVER EXPRESSION OF CLUSTERIN IS AN INDEPENDENT PROGNOSTIC FACTOR FOR NONPAPILLARY RENAL CELL CARCINOMA HIDEAKI MIYAKE, SHOJI HARA, SOICHI ARAKAWA, SADAO KAMIDONO, and ISAO HARA HIDEAKI MIYAKEHIDEAKI MIYAKE , SHOJI HARASHOJI HARA , SOICHI ARAKAWASOICHI ARAKAWA , SADAO KAMIDONOSADAO KAMIDONO , and ISAO HARAISAO HARA View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)69130-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Recent studies have revealed the powerful anti-apoptotic activity of clusterin in several types of malignant tumors. However, the significance of clusterin expression in human renal cell carcinoma has not been well characterized. We determined whether the expression level of clusterin in nonpapillary renal cell carcinoma may be used as predictor of tumor progression and prognosis. Materials and Methods: Total RNA was extracted from 93 nonpapillary renal cell carcinomas obtained at surgery and expression levels of clusterin messenger (m)RNA in these specimens were measured by Northern blot analysis. Findings were analyzed with respect to several clinicopathological factors. Results: There were 48 cases (52%) with strong clusterin mRNA expression and 45 (48%) in which it was weak or nonexistent. The expression level of clusterin mRNA did not significantly correlate with patient gender, age, tumor grade or size, or histological cell type, whereas pathological stage and the incidence of tumor recurrence were closely associated with clusterin expression (p <0.005 and <0.01, respectively). The recurrence-free and overall survival rates in patients with strong clusterin expression were significantly lower than in those with weak or no expression (p <0.05). Furthermore, multivariate analyses revealed that strong expression of clusterin was an independent predictor of tumor recurrence and overall survival (p <0.05). Conclusions: These findings suggest that the over expression of clusterin may be a useful prognostic parameter in patients with nonpapillary renal cell carcinoma after radical nephrectomy. References 1 : Prognostic factors in renal cell carcinoma. Br J Urol1995; 75: 565. Crossref, Medline, Google Scholar 2 : Expression of tumor-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer1995; 71: 863. Crossref, Medline, Google Scholar 3 : Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res2000; 16: 3807. Google Scholar 4 : P53, bcl-2, and Bax expression in renal cell carcinoma. Urology1998; 51: 1057. Crossref, Medline, Google Scholar 5 : Expression of bcl-2, p53 oncoprotein, and proliferating nuclear antigen in renal cell carcinoma. Eur Urol1999; 35: 242. Crossref, Medline, Google Scholar 6 : Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol1995; 27: 633. Crossref, Medline, Google Scholar 7 : SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int1991; 39: 1098. Crossref, Medline, Google Scholar 8 : Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res1991; 51: 162. Medline, Google Scholar 9 : Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J Clin Invest1994; 93: 877. Crossref, Medline, Google Scholar 10 : Prevention of cell death induced by tumor necrosis factor α in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res1995; 55: 2431. Medline, Google Scholar 11 : Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen-independence in prostate cancer. Cancer Res2000; 60: 170. Medline, Google Scholar 12 : Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2, in prostate cancer xenograft models. Cancer Res2000; 60: 2547. Medline, Google Scholar 13 : Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res2000; 6: 1655. Medline, Google Scholar 14 : Gp80 (clusterin; TRPM-2) mRNA levels is enhanced in human renal cell carcinomas. J Cancer Res Clin Oncol1994; 120: 186. Crossref, Medline, Google Scholar 15 : Kidney. In: TNM Classification of Malignant Tumors. New York: International Union Against Cancer1997: 180. Google Scholar 16 : Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst2000; 92: 34. Crossref, Medline, Google Scholar 17 : Urinary tract obstruction. Semin Nephrol2001; 21: 133. Crossref, Medline, Google Scholar 18 : Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. Kidney Int2001; 59: 137. Crossref, Medline, Google Scholar 19 : Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int1998; 53: 1647. Crossref, Medline, Google Scholar 20 : Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal cell carcinoma cells. Mol Urol2001; 5: 105. Crossref, Medline, Google Scholar 21 : Chemosensitization of human renal cell cancer using antisense oligodeoxynucleotides targeting the anti-apoptotic gene clusterin. J Urol2001; 165: 127. Google Scholar From the Department of Urology, Kobe University School of Medicine, Kobe, Japan, and Division of Urology, University of British Columbia, Vancouver, British Columbia, Canada© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Beheshti Namdar A, Kabiri M, Mosanan Mozaffari H, Aminifar E and Mehrad-Majd H (2022) Circulating Clusterin Levels and Cancer Risk: A Systematic Review and Meta-AnalysisCancer Control, 10.1177/10732748211038437, VOL. 29, (107327482110384), Online publication date: 1-Jan-2022. Praharaj P, Patra S, Panigrahi D, Patra S and Bhutia S (2021) Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 10.1016/j.bbcan.2020.188500, VOL. 1875, NO. 2, (188500), Online publication date: 1-Apr-2021. Ren L, Yi J, Li W, Zheng X, Liu J, Wang J and Du G (2019) Apolipoproteins and cancerCancer Medicine, 10.1002/cam4.2587, VOL. 8, NO. 16, (7032-7043), Online publication date: 1-Nov-2019. Merlotti A, Malizia A, Michea P, Bonte P, Goudot C, Carregal M, Nuñez N, Sedlik C, Ceballos A, Soumelis V, Amigorena S, Geffner J, Piaggio E and Sabatte J (2019) Aberrant fucosylation enables breast cancer clusterin to interact with dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN)OncoImmunology, 10.1080/2162402X.2019.1629257, VOL. 8, NO. 9, (e1629257), Online publication date: 2-Sep-2019. Wilson M and Zoubeidi A (2016) Clusterin as a therapeutic targetExpert Opinion on Therapeutic Targets, 10.1080/14728222.2017.1267142, VOL. 21, NO. 2, (201-213), Online publication date: 1-Feb-2017. Nishikawa M, Miyake H, Gleave M and Fujisawa M (2016) Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma ModelTargeted Oncology, 10.1007/s11523-016-0448-3, VOL. 12, NO. 1, (69-79), Online publication date: 1-Feb-2017. Lee J, Lee J, Rho S, Choi J, Lee D, An S, Oh T, Choi D and Lee S (2014) PACAP inhibits tumor growth and interferes with clusterin in cervical carcinomasFEBS Letters, 10.1016/j.febslet.2014.11.004, VOL. 588, NO. 24, (4730-4739), Online publication date: 20-Dec-2014. Chun Y (2014) Knockdown of Clusterin Expression Increases the In Vitro Sensitivity of Human Prostate Cancer Cells to PaclitaxelJournal of Toxicology and Environmental Health, Part A, 10.1080/15287394.2014.951760, VOL. 77, NO. 22-24, (1443-1450), Online publication date: 17-Dec-2014. Ferenczi S, Cserháti M, Krifaton C, Szoboszlay S, Kukolya J, Szőke Z, Kőszegi B, Albert M, Barna T, Mézes M, Kovács K, Kriszt B and Woloschak G (2014) A New Ochratoxin A Biodegradation Strategy Using Cupriavidus basilensis Őr16 StrainPLoS ONE, 10.1371/journal.pone.0109817, VOL. 9, NO. 10, (e109817) Zoubeidi A and Gleave M (2014) Co-targeting Adaptive Survival Pathways Management of Castration Resistant Prostate Cancer, 10.1007/978-1-4939-1176-9_16, (233-248), . MacLeod A and Bennett C (2013) Therapeutic applications of anti-sense mechanisms for the treatment of cancer Molecular Oncology, 10.1017/CBO9781139046947.085, (893-902) Blumenstein B, Saad F, Hotte S, Chi K, Eigl B, Gleave M and Jacobs C (2013) Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration‐resistant prostate cancer treated with custirsenCancer Medicine, 10.1002/cam4.93, VOL. 2, NO. 4, (468-477), Online publication date: 1-Aug-2013. MacLeod A (2013) Antisense therapies for cancerDrug Discovery Today: Therapeutic Strategies, 10.1016/j.ddstr.2013.04.002, VOL. 10, NO. 3, (e157-e163), Online publication date: 1-Nov-2014. Zoubeidi A and Gleave M (2013) Clusterin as a Target for Treatment of Castration-Resistant Prostate Cancer Androgen-Responsive Genes in Prostate Cancer, 10.1007/978-1-4614-6182-1_20, (329-340), . MA X and BAI Y (2012)(2012) IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterinMolecular Medicine Reports, 10.3892/mmr.2012.1110, VOL. 6, NO. 6, (1433-1437), Online publication date: 1-Dec-2012. Harada K, Miyake H, Kusuda Y and Fujisawa M (2012) Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomyBJU International, 10.1111/j.1464-410X.2012.11297.x, VOL. 110, NO. 11c, (E1131-E1137), Online publication date: 1-Dec-2012. Zoubeidi A and Gleave M (2012) Small heat shock proteins in cancer therapy and prognosisThe International Journal of Biochemistry & Cell Biology, 10.1016/j.biocel.2012.04.010, VOL. 44, NO. 10, (1646-1656), Online publication date: 1-Oct-2012. Tousi F, Bones J, Iliopoulos O, Hancock W and Hincapie M (2012) Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinomaJournal of Chromatography A, 10.1016/j.chroma.2012.07.066, VOL. 1256, (121-128), Online publication date: 1-Sep-2012. Kususda Y, Miyake H, Gleave M and Fujisawa M (2012) Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma modelBritish Journal of Cancer, 10.1038/bjc.2012.209, VOL. 106, NO. 12, (1945-1952), Online publication date: 1-Jun-2012. Li J, Jia L, Zhao P, Jiang Y, Zhong S and Chen D (2012) Stable Knockdown of Clusterin by Vector-Based RNA Interference in a Human Breast Cancer Cell Line Inhibits Tumour Cell Invasion and MetastasisJournal of International Medical Research, 10.1177/147323001204000216, VOL. 40, NO. 2, (545-555), Online publication date: 1-Apr-2012. Watari H, Kinoshita R, Han Y, Wang L, Hosaka M, Taguchi H, Tsuchiya K, Tanaka S, Shirato H and Sakuragi N (2012) Prognostic Significance of Clusterin Expression in Advanced-Stage Cervical Cancer Treated With Curative Intended RadiotherapyInternational Journal of Gynecologic Cancer, 10.1097/IGC.0b013e31821a03d9, VOL. 22, NO. 3, (465-470), Online publication date: 1-Mar-2012. Clark G, Grassi P, Pang P, Panico M, Lafrenz D, Drobnis E, Baldwin M, Morris H, Haslam S, Schedin-Weiss S, Sun W and Dell A (2012) Tumor Biomarker Glycoproteins in the Seminal Plasma of Healthy Human Males Are Endogenous Ligands for DC-SIGNMolecular & Cellular Proteomics, 10.1074/mcp.M111.008730, VOL. 11, NO. 1, (M111.008730), Online publication date: 1-Jan-2012. Campbell S and Lane B (2012) Malignant Renal Tumors Campbell-Walsh Urology, 10.1016/B978-1-4160-6911-9.00049-9, (1413-1474.e33), . Cheng C, Cherng S, Wu W, Yang T, Huang X, Liao F, Wu M and Sheu G (2011) Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cellsCancer Chemotherapy and Pharmacology, 10.1007/s00280-011-1682-0, VOL. 69, NO. 1, (145-154), Online publication date: 1-Jan-2012. Hassan M, Watari H, Han Y, Mitamura T, Hosaka M, Wang L, Tanaka S and Sakuragi N (2011) Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxelJournal of Experimental & Clinical Cancer Research, 10.1186/1756-9966-30-113, VOL. 30, NO. 1, Online publication date: 1-Dec-2011. Koupparis A, Casey R, Robinson M and Gleave M (2010) Novel targeted agents on the horizon for castration-resistant prostate cancerFuture Oncology, 10.2217/fon.10.145, VOL. 6, NO. 12, (1883-1895), Online publication date: 1-Dec-2010. Watari H, Kanuma T, Ohta Y, Hassan M, Mitamura T, Hosaka M, Minegishi T and Sakuragi N (2010) Clusterin Expression Inversely Correlates with Chemosensitivity and Predicts Poor Survival in Patients with Locally Advanced Cervical Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical HysterectomyPathology & Oncology Research, 10.1007/s12253-009-9235-0, VOL. 16, NO. 3, (345-352), Online publication date: 1-Sep-2010. Zoubeidi A, Chi K and Gleave M (2010) Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced CancerClinical Cancer Research, 10.1158/1078-0432.CCR-09-2917, VOL. 16, NO. 4, (1088-1093), Online publication date: 15-Feb-2010. Lenferink A, Cantin C, Nantel A, Wang E, Durocher Y, Banville M, Paul-Roc B, Marcil A, Wilson M and O'Connor-McCourt M (2009) Transcriptome profiling of a TGF-β-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodiesOncogene, 10.1038/onc.2009.399, VOL. 29, NO. 6, (831-844), Online publication date: 11-Feb-2010. Gleave M, Cox M and Wang Y (2010) Cell Biology of Prostate Cancer and Molecular Targets Drug Management of Prostate Cancer, 10.1007/978-1-60327-829-4_1, (1-24), . Yang G, Li X and Xie D (2009) Overexpression of Clusterin in Ovarian Cancer is Correlated With Impaired SurvivalInternational Journal of Gynecological Cancer, 10.1111/IGC.0b013e3181a83ed9, VOL. 19, NO. 8, (1342-1346), Online publication date: 1-Nov-2009. Redondo M, Tellez T and Roldan M (2009) The Role of Clusterin (CLU) in Malignant Transformation and Drug Resistance in Breast Carcinomas , 10.1016/S0065-230X(09)05002-7, (21-43), . Chi K, Zoubeidi A and Gleave M (2008) Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancerExpert Opinion on Investigational Drugs, 10.1517/13543780802528609, VOL. 17, NO. 12, (1955-1962), Online publication date: 1-Dec-2008. Park D, Yeo S, Wilson M, Yerbury J, Kwong J, Welch W, Choi Y, Birrer M, Mok S and Wong K (2008) Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian CancerNeoplasia, 10.1593/neo.08604, VOL. 10, NO. 9, (964-IN7), Online publication date: 1-Sep-2008. Watari H, Ohta Y, Hassan M, Xiong Y, Tanaka S and Sakuragi N (2008) Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomyGynecologic Oncology, 10.1016/j.ygyno.2007.11.026, VOL. 108, NO. 3, (527-532), Online publication date: 1-Mar-2008. Park H, Kim J, Lee C, Lee W, Lee S, Lee J and Chung M (2007) The Relationship of Clusterin Expression with Ki-67 Expression and Clinicopathological Factors in Human Renal Cell CarcinomaKorean Journal of Urology, 10.4111/kju.2007.48.3.244, VOL. 48, NO. 3, (244), . Sullivan P, Rao J, Cheng L and Cote R (2007) Classical pathology versus molecular pathology in renal cell carcinomaCurrent Urology Reports, 10.1007/s11934-007-0015-7, VOL. 8, NO. 1, (5-11), Online publication date: 1-Jan-2007. Park D, Geun Yeo S, Young Shin E, Mok S and Hoon Kim D (2006) Clusterin confers paclitaxel resistance in cervical cancerGynecologic Oncology, 10.1016/j.ygyno.2006.06.037, VOL. 103, NO. 3, (996-1000), Online publication date: 1-Dec-2006. Miyake H, Hara I, Fujisawa M and Gleave M (2006) The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancerExpert Opinion on Investigational Drugs, 10.1517/13543784.15.5.507, VOL. 15, NO. 5, (507-517), Online publication date: 1-May-2006. Harada K, Sakai I, Ishimura T, Inoue T, Hara I and Miyake H (2006) Clinical symptoms in localized renal cell carcinoma reflect its invasive potential: Comparative study between incidentally detected and symptomatic diseasesUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2005.07.008, VOL. 24, NO. 3, (201-206), Online publication date: 1-May-2006. Rouvière O, Bouvier R, Négrier S, Badet L and Lyonnet D (2006) Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?Nature Clinical Practice Oncology, 10.1038/ncponc0479, VOL. 3, NO. 4, (200-213), Online publication date: 1-Apr-2006. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T, Zhang G, Kondo K, Nosé V and Kaelin W (2006) Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor ProteinThe American Journal of Pathology, 10.2353/ajpath.2006.050867, VOL. 168, NO. 2, (574-584), Online publication date: 1-Feb-2006. Chi K, Eisenhauer E, Fazli L, Jones E, Goldenberg S, Powers J, Tu D and Gleave M (2005) A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2′-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate CancerJNCI: Journal of the National Cancer Institute, 10.1093/jnci/dji252, VOL. 97, NO. 17, (1287-1296), Online publication date: 7-Sep-2005. Kang Y, Hong S, Lee H and Kim W (2004) Overexpression of clusterin in human hepatocellular carcinomaHuman Pathology, 10.1016/j.humpath.2004.07.021, VOL. 35, NO. 11, (1340-1346), Online publication date: 1-Nov-2004. Chung J, Kwak C, Jin R, Lee C, Lee K and Lee S (2004) Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitroCancer Letters, 10.1016/j.canlet.2003.07.008, VOL. 203, NO. 2, (155-161), Online publication date: 1-Jan-2004. Kirkali Z and Lekili M (2003) Renal cell carcinoma: new prognostic factors?Current Opinion in Urology, 10.1097/00042307-200311000-00002, VOL. 13, NO. 6, (433-438), Online publication date: 1-Nov-2003. Whang Y and Godley P (2003) Renal cell carcinomaCurrent Opinion in Oncology, 10.1097/00001622-200305000-00006, VOL. 15, NO. 3, (213-216), Online publication date: 1-May-2003. Han K, Pantuck A and Belldegrun A (2003) Basic Biology and Clinical Behavior of Renal Cell Carcinoma Kidney Cancer, 10.1007/978-1-4615-0451-1_4, (69-89), . Volume 167Issue 2 Part 1February 2002Page: 703-706 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordscarcinoma, renal cellkidneyprognosistumor markers, biologicalglycoproteinsMetrics Author Information HIDEAKI MIYAKE More articles by this author SHOJI HARA More articles by this author SOICHI ARAKAWA More articles by this author SADAO KAMIDONO More articles by this author ISAO HARA Requests for reprints: Department of Urology, Kobe University School of Medicine, 7–5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. More articles by this author Expand All Advertisement PDF downloadLoading ...